Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic
OPKO Health and Entera Bio have entered into a collaboration agreement to develop the first oral dual agonist GLP-1/glucagon peptide tablet for treating obesity and metabolic disorders. Key details include:
-
The program combines OPKO's long-acting oxyntomodulin analog (OPK-88006) with Entera's N-Tab oral delivery technology.
-
OPKO will have a 60% ownership stake and Entera will have a 40% stake in the program, with corresponding cost-sharing responsibilities.
-
OPKO purchased 3,685,226 Entera shares at $2.17 per share to fund Entera's Phase 1 development costs.
-
After Phase 1, Entera can maintain its 40% stake by continuing funding, or opt-out to retain 15% ownership while OPKO increases to 85%.
-
Favorable pharmacodynamic, pharmacokinetic and bioavailability data was reported in September 2024.
-
The companies plan to file an Investigational New Drug application with the FDA later in 2025.
-
This would be the first oral dual GLP-1/glucagon agonist to enter clinical development.
-
The treatment aims to suppress appetite, induce weight loss, and provide cardioprotective and anti-fibrotic benefits.
-
Currently, there are no approved dual GLP-1/glucagon agonists available on the market.
This collaboration represents a significant step in developing a potentially first-in-class oral therapy for obesity and metabolic disorders, combining OPKO's peptide expertise with Entera's oral delivery technology.